Test Catalog

Test Id : GBETH

Not Orderable

General Factor Bethesda Units, Plasma

Download
Overview

Test Catalog

Useful For
Suggests clinical disorders or settings where the test may be helpful

Detecting and quantifying the presence and titer of a specific factor inhibitor directed against a specific coagulation factor

Method Name
A short description of the method used to perform the test

Only orderable as a reflex. For more information see:

-ALBLD / Bleeding Diathesis Profile, Limited, Plasma

-ACBL / Bleeding Diathesis Profile, Comprehensive, Plasma

-APROL / Prolonged Clot Time Profile, Plasma

-2INHE / Factor II Inhibitor Evaluation, Plasma

-7INHE / Factor VII Inhibitor Evaluation, Plasma

-10INE / Factor X Inhibitor Evaluation, Plasma

-11INE / Factor XI Inhibitor Evaluation, Plasma

 

Optical Clot-Based

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

General Factor Bethesda Units, P

Aliases
Lists additional common names for a test, as an aid in searching

Factor II Inhibitor

Factor VII Inhibitor

Factor X Inhibitor

Factor XI Inhibitor

Specimen Type
Describes the specimen type validated for testing

Plasma Na Cit

Ordering Guidance

If type of inhibitor is unknown, see APROL / Prolonged Clot Time Profile, Plasma.

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Only orderable as a reflex. For more information see:

-ALBLD / Bleeding Diathesis Profile, Limited, Plasma

-APROL / Prolonged Clot Time Profile, Plasma

-2INHE / Factor II Inhibitor Evaluation, Plasma

-7INHE / Factor VII Inhibitor Evaluation, Plasma

-10INE / Factor X Inhibitor Evaluation, Plasma

-11INE / Factor XI Inhibitor Evaluation, Plasma

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Plasma Na Cit Frozen 14 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

Detecting and quantifying the presence and titer of a specific factor inhibitor directed against a specific coagulation factor

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Significant bleeding can result from the presence of a coagulation factor inhibitor and could be life threatening. Whether the inhibitor is present due to hemophilia or is of an acquired nature, it greatly complicates the treatment process of a decreased factor level. The titer of the inhibitor may determine the mode of treatment. Bethesda units are a standardization to give a uniform definition of an inhibitor.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Only orderable as a reflex. For more information see:

-ALBLD / Bleeding Diathesis Profile, Limited, Plasma

-ACBL / Bleeding Diathesis Profile, Comprehensive, Plasma

-APROL / Prolonged Clot Time Profile, Plasma

-2INHE / Factor II Inhibitor Evaluation, Plasma

-7INHE / Factor VII Inhibitor Evaluation, Plasma

-10INE / Factor X Inhibitor Evaluation, Plasma

-11INE / Factor XI Inhibitor Evaluation, Plasma

 

< or =0.5 Bethesda Units

Interpretation
Provides information to assist in interpretation of the test results

An interpretive report will be provided when testing is complete.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

No significant cautionary statements

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Biggs R, Bidwell E. A method for the study of antihemophiliac globulin inhibitors with reference to six cases. Br J Haematol. 1959;5:379-395

2. Hoyer LW: Factor VIII inhibitors. In: Hoyer LW, eds. Progress in Clinical and Biological Research. Vol 150. R Alan Liss Inc, 1984:87-98

3. Kasper CK, Aledort L, Aronson D, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34(2):61

4. Kasper C, Ewing N. Acquired inhibitors of plasma coagulation factors. J Med Tech 1986;38:431-439

5. Kottke-Marchant K, ed: Laboratory Hematology Practice. Wiley Blackwell Publishing; 2012

6. Hoffman R, Benz Jr EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 7th ed. Elsevier; 2018

Method Description
Describes how the test is performed and provides a method-specific reference

Undiluted patient plasma and serially diluted patient plasma are mixed with an equal volume of normal pooled plasma (NPP). The NPP supplies the factor against which the inhibitor is directed in a known concentration. The patient plasma mixtures, along with a control (Bethesda Pool) of diluted NPP are incubated at 37 degrees C for 2 hours, after which factor activity is measured. The factor activity in the undiluted patient and its serial dilutions are compared to the factor activity recovered in the Bethesda Pool. These values are then used to calculate Bethesda units. One Bethesda unit is defined as the amount of antibody that will destroy 50% of the coagulation factor activity in 2 hours.( Owen CA Jr, Bowie EJW, Thompson JH Jr: Diagnosis of Bleeding Disorders. 2nd ed. Little, Brown and Company; 1975; Meijer P, Verbruggen HW, Spannagi M: Clotting factors and inhibitors: Assays and interpretation. In: Kottke-Marchant K, ed. Laboratory Hematology Practice. Wiley Blackwell Publishing; 2012:435-446)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Monday through Friday

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

2 to 5 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

7 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees :
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

85335

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
GBETH General Factor Bethesda Units, P 13591-3
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
607434 General Factor Bethesda Units, P 13591-3

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports